Form 4: Avidity Director Sells Shares in Novartis Merger

Avidity Biosciences Director Simona Skerjanec disposed of all her common stock and stock options as part of the merger agreement with Novartis AG.

Summary

• Director Simona Skerjanec reported the disposal of all her beneficial ownership in Avidity Biosciences, Inc. on February 27, 2026.
• The transactions were executed pursuant to the Agreement and Plan of Merger, dated October 25, 2025, between Novartis AG, Ajax Acquisition Sub, Inc., and Avidity Biosciences, Inc.
• Ms. Skerjanec disposed of 6,692 shares of Avidity Biosciences, Inc. common stock.
• She also disposed of 10,034 stock options with an exercise price of $33.62 and 42,308 stock options with an exercise price of $28.91.
• The stock options were disposed of in exchange for a cash payment equal to the merger consideration of $72.00 per share minus the respective exercise prices.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for Avidity shareholders, as the merger consideration represents a clear exit strategy and value realization. The transaction itself is a procedural step following a significant corporate event.

Positives

• The merger consideration of $72.00 per share indicates a premium for shareholders and option holders, allowing for value realization.
• Option holders received a cash payment for their in-the-money options, reflecting the value created by the merger.

Negatives

• The director's beneficial ownership in Avidity Biosciences, Inc. is now zero, signifying the completion of the merger and the cessation of Avidity's independent public operations.

Future Outlook

The filing indicates the completion of a merger, implying Avidity Biosciences, Inc. will no longer operate as an independent public entity. The future outlook for the former Avidity assets will be integrated into Novartis AG's strategic plans.

Industry Context

StockSavvy.ai notes that this transaction reflects the ongoing consolidation within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire innovative smaller biotechs to bolster their pipelines and technology platforms. The acquisition by Novartis AG of Avidity Biosciences, Inc. suggests a strategic interest in Avidity's RNA-based therapeutics.

Comparison to Industry Standards

• The merger consideration of $72.00 per share for Avidity Biosciences, Inc. can be compared to recent biotech acquisitions, such as Pfizer's acquisition of Seagen for $43 billion ($229 per share) or Merck's acquisition of Prometheus Biosciences for $10.8 billion ($200 per share). While the per-share value differs due to company size and stage, the premium paid over pre-announcement prices is a key metric for evaluating such deals.
• The cash-out of in-the-money options at the merger price minus exercise price is a standard practice in M&A transactions, ensuring all equity holders receive fair value based on the deal terms.

Stakeholder Impact

• Shareholders: Existing shareholders of Avidity Biosciences, Inc. receive $72.00 per share in cash, representing a definitive value realization.
• Employees: The merger will likely lead to integration efforts, potentially impacting Avidity employees through changes in roles, reporting structures, or location, though specific details are not in this filing.

Next Steps

• Integration of Avidity Biosciences' operations and assets into Novartis AG.
• Further regulatory filings related to the merger's finalization and delisting of Avidity Biosciences, Inc. shares.

Key Dates

Recommendation

The filing details a director's disposal of all beneficial ownership in Avidity Biosciences, Inc. due to the previously announced merger with Novartis AG at $72.00 per share. With the merger agreement in place, the stock's price is expected to converge to the acquisition price, limiting further upside. Existing shareholders should hold to receive the merger consideration, while new investment opportunities are minimal.

Keywords

Avidity Biosciences, RNAM, Novartis AG, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Common Stock, Simona Skerjanec